Medical therapy of paediatric inflammatory bowel disease

Nature Reviews Gastroenterology & Hepatology, Published online: 16 September 2022; doi:10.1038/s41575-022-00686-8Antibodies targeting tumour necrosis factor have substantially advanced the treatment of paediatric inflammatory bowel disease. Understanding pharmacokinetics and therapeutic drug monitoring has led to increased efficacy and durability of response. Primary non-response is more common in ulcerative colitis than in Crohn’s disease, highlighting the need for alternative biologic agents and oral small molecules.
Source: Nature Reviews Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research